October 06, 2016

Abstracts Presented at the European Association for Clinical Pharmacology and Therapeutics Focus Meeting 06-09 October 2016

1-Efficacy

Accelerated Approval Paths: What they do Mean and What they Should Not Mean?
• G. Calvo
Published in issue: October 06, 2016
e1

Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus
• Z. Milicevic
Published in issue: October 06, 2016
e1

Clinical Drug-Drug Interaction Studies: Methods, Pitfalls, and Interpretation
• J.T. Backman
Published in issue: October 06, 2016
e1-e2

The Role of the National Competent Authority (NCA) In the Assessment of Medicinal Products in the National Procedure
• S. Tomic
Published in issue: October 06, 2016
e2

Evaluation of Drugs in the Pediatric Population
• S. Mimica Matanovic
Published in issue: October 06, 2016
e2

Efficacy of Antidepressants: Issues Related to Bias in Clinical Trials
• E. Spina
Published in issue: October 06, 2016
e2

New Methods and Designs of Clinical Trials
• C. Pontes
Published in issue: October 06, 2016
e2-e3

Current Challenges and Hurdles in New Drug Development
• S. Vukicevic
Published in issue: October 06, 2016
e3

How to Promote Clinical Research in Cee?
• R. Spaventi
Published in issue: October 06, 2016
e3

Medicinal Product Regulation: Portugal’s Framework
• M.T. Herdeiro,
• P.A. Dias Bastos,
• A. Teixeira Rodrigues,
• F. Roque
Published in issue: October 06, 2016
e3-e4

Inconsistency in Preclinical and Clinical Trials Exploring The Role of Hormone Replacement Therapy in Alzheimer’s Disease
• J. Osmanovic-Barilar,
• M. Salkovic-Petrisic
Published in issue: October 06, 2016
e4

The Effects of SENS-111, A New H4R Antagonist, On Vertigo Induced by Caloric Test in Healthy Volunteers (HV) is Related to Plasma Concentrations
• P. Attali,
• R. Gomeni,
• E. Wersinger,
• S. Poli,
• F. Venail
Published in issue: October 06, 2016
e4

Are we Scared of Clinical Trials if not Sufficiently Informed and Educated?
• L. Burnazovic-Ristic,
• M. Rakanovic-Todic,
• S. Maleskic,
• A. Kulo Cesic,
• J. Kusturica
Published in issue: October 06, 2016
e4-e5

Attitudes to Performing Clinical Trials
• I. Potocnjak,
• E. Nham,
• V. Degoricija
Published in issue: October 06, 2016
e5


2-Effectiveness

Personalised Medicine Approaches For Identifying Effective Therapies
• D.R.J. Singer
Published in issue: October 06, 2016
e7

The Role Of Pharmacogenetics In Individualized Treatment Choices
• N. Bozina
Published in issue: October 06, 2016
e7

Clinical Pharmacology As A Key Principle Of Precision Medicine In Korea
• J.G. Shin
Published in issue: October 06, 2016
e7

Regulation Of Orphan Medicinal Products In Europe: History Trends And Challenges
• B. Sepodes
Published in issue: October 06, 2016
e7-e8

Safe Introduction of New Medicines Into Clinical Practice
• S. Maxwell
Published in issue: October 06, 2016
e8

Vascular Consequences Of Interruption Of Tnf-Inhibitor Therapy In Patients With Rheumatoid Arthritis
• G.A. Rongen,
• I. Van Ingen,
• T.L. Jansen
Published in issue: October 06, 2016
e8

Effectiveness Assessment When Pharmacokinetics Makes A Difference, Macrolides And Azalide Example
• I. Francetic
Published in issue: October 06, 2016
e8-e9

New drugs for bad bugs: what’s new and what’s in the pipeline?
• V. Erdeljic Turk,
• I. Simic,
• R. Likic,
• ...
• I. Cegec,
• D. Juricic Nahal,
• I. Kraljickovic
Published in issue: October 06, 2016
e9

Osteogrow Development: Bmp6 Bone Device For Enhancing Bone Healing
• L. Grgurevic
Published in issue: October 06, 2016
e9-e10

Food And Drug Interactions
• M. Bago,
• J. Culig
Published in issue: October 06, 2016
e10

Clinically Guided Warfarin Dose Versus Genotyping In Early Achievement Of Stable Anticoagulant Effect Of Warfarin
• K. Makar-Ausperger,
• N. Bozina,
• V. Erdeljic Turk,
• ...
• M. Radacic Aumiler,
• L. Ganoci,
• I. Francetic
Published in issue: October 06, 2016
e10

The Analysis Of Lipid Modifying Agents Usage In Croatia During The Fifteen-Year Period
• M. Kucan,
• D. Vitezic
Published in issue: October 06, 2016
e10

The Role Of Cyp2d6, Cyp3a4/5, And Abcb1 Polymorphisms In Patients Using Long-Acting Injectable Risperidone
• L. Ganoci,
• M. Lovrić,
• M. Živković,
• M. Šagud,
• I. Klarica Domjanović,
• N. Božina
Published in issue: October 06, 2016
e10-e11

Adherence To Pharmacological Treatment Of Chronic Non-Malignant Pain In Individuals Aged 65 and Older
• F. Markotic,
• E. Cerni Obrdalj,
• A. Zalihic,
• ...
• A. Banozic,
• D. Sapunar,
• L. Puljak
Published in issue: October 06, 2016
e11

Genetic and Non-Genetic Factors Affecting The Response To Clopidogrel Therapy
• S. Mugosa,
• M. Sahman-Zaimovic,
• Z. Todorovic,
• Z. Bukumiric,
• I. Radosavljevic,
• N. Djordjevic
Published in issue: October 06, 2016
e11


3-Economics

Pharmacoeconomics: How It Can Be Applied To Support Decisions In Health Care?
• D. Vitezic
Published in issue: October 06, 2016
e13

Rapid Health Technology Assessment Of New Medicines: Lessons From 15 Years Experience In Scotland
• K.R. Paterson
Published in issue: October 06, 2016
e13

A Model For Managed Introduction Of New Medicines In Sweden
• Y. Böttiger
Published in issue: October 06, 2016
e13-e14

How To Assess The Value Of The Drug? An Overview On Producing Economic Evidence In The R&D Process
• Z. Kaló
Published in issue: October 06, 2016
e14

Evaluation Of Medicines For Reimbursement By The National Social Insurance Institutions In Austria
• T. Griesbacher,
• R. Sauermann
Published in issue: October 06, 2016
e14

Current Situation And Future Directions For Health Technology Assessment In Europe
• F. Meyer
Published in issue: October 06, 2016
e14-e15

Clinical Safety and Efficacy Issues Ariding in Relation to Alternative Formulations of nti Drugs Relevant to National Policy Development and Reimbursement Decisions – Focus on Calcineurin Inhibitors (cni)
• N. Undre
Published in issue: October 06, 2016
e15

Cost Utility Analysis Of Selected Medical Equipment And Procedures In Croatia
• D. Korolija Marinic,
• S. Varga
Published in issue: October 06, 2016
e15

Managing Increasing Expenses For Oncology Treatment In Lower Income Countries In Europe
• Slobodanka Bolanča,
• Jernej Makovec
Published in issue: October 06, 2016
e15-e16

Outlook For Biosimilar Molecules Entering Croatian Pharmaceutical Market In The Period From 2016 To 2020
• R. Likic,
• I. Simic,
• V. Erdeljic Turk,
• ...
• I. Cegec,
• D. Juricic Nahal,
• I. Kraljickovic
Published in issue: October 06, 2016
e16

Health Technology Assessment (Hta) In Croatia: National And International View
• M. Huic
Published in issue: October 06, 2016
e16

Comparison Of Sorafenib Cost-Effectiveness And Budget Impact When Used For Advanced Hepatocellular Carcinoma In Two Neighbouring Balkan Countries
• S.M. Jankovic,
• M. Kostic,
• J. Milovanovic
Published in issue: October 06, 2016
e16-e17

Decentralized Decision Making On Drug Reimbursement In A Middle-Income Country: Case Of Bosnia And Herzegovina
• M. Mahmic-Kaknjo,
• A. Marusic
Published in issue: October 06, 2016
e17

Direct Medical Costs Of Treating Colorectal Cancer Patients With Different Chemotherapy Protocols Regarding Stage And Outcome Of The Disease
• A. Kovacevic,
• Z. Segrt,
• D. Tarabar,
• N. Rancic,
• M. Jakovljevic,
• V. Dragojevic-Simic
Published in issue: October 06, 2016
e17

Pharmaceutical Pricing: How Much for The Risk Of Non-Cure?
• D. Mance,
• D. Mance,
• D. Vitezic
Published in issue: October 06, 2016
e17-e18

Why Abc/Ved Analysis In Oncology? The Experience Of A Major Russian Oncology Center
• A.V. Pavlysh,
• A.S. Kolbin
Published in issue: October 06, 2016
e18


Workshops

Excellence in Clinical Research: Clinical Trial Design
• T. Simon
Published in issue: October 06, 2016
e19

Implementation of Pharmacoeconomics to Support Pharmaceutical R&D Decisions Workshop
• Z. Kaló,
• D. Vitezic
Published in issue: October 06, 2016
e19


Posters (1)

Availability of Information on use of Medicines in Children in Reference Books
• M.V. Melikyan,
• L.N. Vardanyan,
• I.A. Kazaryan,
• A.L. Sevikyan
Published in issue: October 06, 2016
e21

Effects of Celastrol on Bv-2 Microglial Cells Exposed to in Vitro Hypoxia
• V. Rački,
• M. Marcelić,
• J. Mršić-Pelčić,
• N. Kučić
Published in issue: October 06, 2016
e21

Pregnancy Exposure to Drugs: Role of Clinical Pharmacologist
• M. Radacic Aumiler,
• V. Erdeljic Turk,
• K. Makar-Ausperger,
• R. Likic,
• L. Bielen,
• I. Simic
Published in issue: October 06, 2016
e21